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Replacement therapy for iron deficiency improves exercise capacity 
and quality of life in patients with cyanotic congenital heart disease 
and/or the Eisenmenger syndrome 
 
 
1. RESUM (EN CATALÀ) 
 
La teràpia suplementària de ferro millora la capacitat d’exercici i la 
qualitat de vida en malalts amb una cardiopatia congènita cianòtica 
i/ o síndrome d’Eisenmenger 
 
El dèficit de ferro és una troballa comú en la cardiopatia congènita cianòtica, i 
pot ser la causa d’una reducció en la capacitat d’exercici. Actualment, està indicada la 
reposició dels dipòsits de ferro en aquest grup de malalts, éssent les evidències 
científiques escasses. En el present treball investiguem la seguretat i eficàcia del 
tractament amb ferro en malalts amb una cardiopatia congènita cianòtica. Per tal 
motiu, vint-i-cinc malalts amb una cardiopatia congenita cianòtica i dèficit de ferro 
van ser inclosos de forma prospectiva entre Agost del 2008 i Gener del 2009. El 
tractament utilitzat fou fumarat ferròs oral, fins a una dosi màxima de 200 mg tres 
vegades al dia. En l’anàlisi basal i als tres mesos de seguiment es va utilitzar el test de 
qualitat de vida “CAMPHOR”, el test de la marxa dels 6 minuts i la prova d’esforç 
amb consum d’oxigen. L’edat mitja fou 39.9+/-10.9 anys, 80% dones. Catorze malalts 
tenien la síndrome d’Eisenmenger, sis una malaltia cianòtica complexa i cinc 
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circulació de Fontan. Cap d’ells va haver d'interrompre el tractament degut a efectes 
adversos. Després de tres mesos de tractament, l’hemoglobina (19.0+/-2.9g/dL a 
20.4+/-2.7g/dL, p<0.001), ferritina (13.3+/-4.7mug/L a 54.1+/-24.2mug/L, p<0.001) i 
saturació de transferrina (17.8+/-9.6% a 34.8+/-23.4%, p<0.001) van augmentar 
significativament. També hi va haver una millora significativa en la puntuació del test 
de qualitat de vida (20.7+/-10.9 a 16.2+/-10.4, p=0.001) i el test de la marxa (371.7+/-
84.7m a 402.8.0+/-74.9m, p=0.001). No es van evidenciar canvis significatius en els 
valors de consum d’oxigen (40.7+/-9.2% a 43.8+/-12.4%, p=0.15). En definitiva, la 
teràpia suplementària amb ferro en els malats amb una cardiopatia congènita cianòtica 
i dèficit de ferro és segura i millora la qualitat de vida i la capacitat funcional. En 
aquest grup de malalts, per tant, és aconsellable identificar el dèficit de ferro i 
restaurar-ne els seus dipòsits.  
 
Paraules clau: Síndrome d’Eisenmenger, cardiopatia congènita cianòtica, dèficit de 




Replacement therapy for iron deficiency improves exercise capacity 
and quality of life in patients with cyanotic congenital heart disease 
and/or the Eisenmenger syndrome 
 
 
Iron deficiency is common in cyanotic congenital heart disease (CHD) and results in 
reduced exercise tolerance. Currently, iron replacement is advocated with limited 
evidence in cyanotic CHD. We investigated the safety and efficacy of iron 
replacement therapy in this population. METHODS: Twenty-five iron-deficient 
cyanotic CHD patients were prospectively studied between August 2008 and January 
2009. Oral ferrous fumarate was titrated to a maximum dose of 200mg thrice-daily. 
The CAMPHOR QoL questionnaire, 6minute walk test (6MWT) and 
cardiopulmonary exercise testing were conducted at baseline and after 3months of 
treatment. RESULTS: Mean age was 39.9+/-10.9years, 80% females. Fourteen had 
Eisenmenger syndrome, 6 complex cyanotic disease and 5 Fontan circulation. There 
were no adverse effects necessitating termination of treatment. After 3months of 
treatment, hemoglobin (19.0+/-2.9g/dL to 20.4+/-2.7g/dL, p<0.001), ferritin (13.3+/-
4.7mug/L to 54.1+/-24.2mug/L, p<0.001) and transferrin saturation (17.8+/-9.6% to 
34.8+/-23.4%, p<0.001) significantly increased. Significant improvements were also 
detected in the total CAMPHOR score (20.7+/-10.9 to 16.2+/-10.4, p=0.001) and 
6MWT distance (371.7+/-84.7m to 402.8.0+/-74.9m, p=0.001). Peak VO(2) remained 
unchanged (40.7+/-9.2% to 43.8+/-12.4% of predicted, p=0.15). CONCLUSION: 
Three months of iron replacement therapy in iron-deficient cyanotic CHD patients 
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was safe and resulted in significant improvement in exercise tolerance and quality of 
life. Identification of iron deficiency and appropriate replacement should be 
advocated in these patients.  
 
 
Keywords: Eisenmenger syndrome, Cyanotic heart disease, Iron deficiency, exercise 




Replacement therapy for iron deficiency improves exercise capacity 
and quality of life in patients with cyanotic congenital heart disease 
and/or the Eisenmenger syndrome 
 
Introduction 
Cyanosis is present in 10 to 20% of adult patients with congenital heart disease 
(CHD) and is considered a complex multisystemic disorder. Chronic hypoxia in these 
patients results in an increase in hemoglobin concentration (secondary 
erythrocytosis). This is a physiologic adaptation aimed at increasing oxygen delivery 
to peripheral tissues by an increase in oxygen carrying capacity and total blood 
volume.1-3 The optimal hemoglobin concentration varies between patients and is 
modulated through the increased production of erythropoietin which depends 
primarily on oxygen saturation at rest and during effort.3, 4 
Iron is a vital substrate for hemoglobin production and sufficient iron stores 
are necessary to achieve and maintain adequate levels of hemoglobin. Unfortunately, 
more than one third of patients with cyanotic heart disease are iron deficient.5, 6 
Possible causes of iron deficiency include increased iron consumption through 
increased erythropoiesis, inappropriate venesections, hemoptysis, bleeding from 
arteriovenous malformations or collateral vessels, abnormal hemostasis, limited 
dietary intake or absorption, and use of anticoagulants and antiplatelets. Iron 
deficiency has also been identified as a risk factor for cerebrovascular events.7 
Moreover, it is associated with exercise intolerance through reduced oxygen delivery 
and its effect on skeletal muscle cell metabolism.8, 9 Iron deficiency may remain 
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undetected in cyanotic patients since common findings as microcytosis are rarely 
found. Increased awareness is, thus, essential and routine monitoring of the peripheral 
red blood cells and iron-related parameters may aid in the prompt detection of iron-
deficiency anemia in patients with cyanotic heart disease. 
 
At present, there are limited data on the management of cyanotic patients with 
iron deficiency. Recent guidelines recommend avoidance of inappropriate venesection 
and cautious treatment of iron deficient cyanotic patients with close monitoring of 
hemoglobin levels.10, 11However, data are lacking on the efficacy of iron 
supplementation on exercise capacity in this population. Moreover, while caution to 
avoid over treatment and excessive erythrocytosis is recommended, no prospective 
trials have addressed the safety of iron supplementation in this cohort. We aimed to 
investigate the safety of iron supplementation in iron deficient cyanotic CHD patients 




This was a prospective, single center, non-randomized study. The protocol closely 
follows routine practice in our center and was approved by the local Ethics 
Committee. All cyanotic patients (resting oxygen saturation of ≤90% after 5 minutes 
of rest) followed at our center not on iron supplements, who were able to undergo 
exercise testing were systematically screened between February 2008 to January 2009 
for iron deficiency (Figure 1). This was defined as serum ferritin<30ug/L or serum 
ferritin<50ug/L and transferrin saturation<15%.12, 13 Exclusion criteria were 1) 
pregnancy; 2) overt anemia (defined as hemoglobin < 11.5 g/ dl) or active bleeding; 
3) known hypersensitivity to iron supplements; 4) patients who were recently initiated 
on advanced therapies for pulmonary hypertension and  5) patients with severe 
hyperviscosity symptoms at the time of screening, as classified by Perloff et al.14 
These hyperviscosity symptoms included headaches, dizziness, altered mentation, 
visual disturbances, parasthesia, tinnitus, fatigue and muscle aches. Patients fulfilling 
the above criteria and agreeing to participate constituted our study population.  
Baseline assessment 
Baseline pretreatment assessment included a clinical interview and physical 
examination. Blood tests included full blood count, transferrin saturation, ferritin, 
creatinine and alanine transaminase levels. All patients completed a CAMPHOR QoL 
questionnaire, a six-minute walk test (6MWT) and a cardiopulmonary exercise test 
(CPET) as described below.  
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Quality of Life assessment 
 
The CAMPHOR questionnaire was used for assessing quality of life. This is a 
questionnaire designed specifically for patients with pulmonary arterial hypertension 
(PAH) and was selected because a significant proportion of cyanotic CHD patients 
have PAH.15 It has been validated in patients with PAH and has a good 
reproducibility, excellent internal consistency and is more sensitive to changes in 
clinical status compared to the other non-specific QoL instruments.16 
 
The CAMPHOR questionnaire addresses two components of QoL: a generic 
and a Health related QoL (HRQoL) component. Generic QoL refers to an individual’s 
subjective perception of satisfaction of life in areas that he/she considers important. 
Completing this section of the questionnaire gives the QoL score. HRQoL is restricted 
to aspects of life which are affected by disease and are potentially modifiable with 
treatment. The HRQoL component of the CAMPHOR questionnaire assesses 
impairment and disability separately. Impairment may result from the loss of physical, 
psychological or physiological function and leads to specific symptoms. Completing 
this part of the questionnaire, thus, provides a symptom score. Disability is described 
as any restriction of lack of ability to complete tasks deemed normal. The activity 
score is obtained in this section after completing this part of the questionnaire.  
The individual CAMPHOR scores are combined to provide a total CAMPHOR 
score. High scores are associated with reduced QoL. 
 
Six minute walk test 
This test was conducted by a single operator in a 20m indoor, marked corridor, 
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following the American Thoracic Society guidelines.17 Heart rate, pulse oximetry and 
Borg scale were recorded at baseline and 6 minutes. 
Cardiopulmonary exercise testing 
This was performed on a treadmill using an incremental maximal exercise 
protocol, which includes a stage 0 during which patients walk at a velocity of 1 mph 
at a 5% gradient (modified Bruce protocol). A respiratory mass spectrometer (Ultima 
PFX, Medgraphics Cardiorespiratory Diagnostics, St Paul, USA) was used to measure 
minute ventilation (VE), carbon dioxide production (VCO2) and oxygen consumption 
(VO2). Patients were encouraged to exercise to exhaustion. Peak VO2, VE/VCO2 
slope and anaerobic threshold (AT) were measured and recorded. Peak VO2 was 
expressed as the percentage of predicted for age, gender, height and weight. The 
VE/VCO2 slope was obtained by linear regression of data acquired through the entire 
period of exercise.18 
 
Iron replacement 
Iron replacement consisted of oral ferrous fumarate 200mg once a day for 1 
week, followed by 200mg twice daily for the next week and finally to the target dose 
of 200mg three times daily. This iron formulation contains 66mg of elemental iron 
per tablet, thus providing the recommended dose of 150-200mg of elemental iron per 
day for oral treatment of iron deficiency anemia in adults. Patients unable to tolerate 
oral therapy received intravenous iron replacement. For this purpose, patients were 
admitted to hospital and received a single dose of intravenous iron sucrose 200mg. 
Iron stores were then reassessed after 1 month and intravenous replacement repeated 
if found to be still iron deficient.  
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Follow up and outcomes  
All investigations performed at baseline were repeated at the 3-month follow-
up visit. Moreover, all adverse events during the 3-month follow-up period were 
recorded, with particular attention to hyperviscosity symptoms. Patients were also 
urged to report possible adverse effects of iron replacement, such as abdominal 
cramps, constipation, heartburn, nausea, and vomiting. 
 
The primary measure of efficacy was change in 6MWT distance after 3 
months of iron replacement. Other measures of efficacy included change in total 
CAMPHOR score and peak VO2.  
Statistical analysis 
In order to detect a change in 6MWT distance of 35m, with a standard 
deviation of 67m, at a two-sided significance level of 0.05 and a power of 80% 
(paired comparison), 24 patients were recruited. Continuous variables are expressed 
as mean±SD and compared between baseline and follow-up using the Wilcoxon 
signed rank test. The relation between change in hemoglobin concentration and 
baseline hemoglobin levels was assessed using linear regression. All p-values were 
two-sided and a p-value of less than 0.05 was considered to indicate statistical 
significance. Analyses were performed using R version 2.8.1 (R Foundation for 





A total of 123 adult cyanotic CHD patients were screened. Of these, 32 were 
found to be iron deficient. One patient was excluded due to pregnancy and 6 patients 
were not keen to participate in the study. No patients were excluded for the presence 
of severe hyperviscosity symptoms. Twenty-five patients were eventually recruited in 
the study. One patient dropped out of the study during follow-up as she underwent 
cardiac surgery for pulmonary artery debanding and could not attend the follow-up 
appointment.  
The mean age of participants was 39.9±10.9 years and the majority were 
females (80%) (Table1). Fourteen patients (56%) had Eisenmenger syndrome, 5(20%) 
had a Fontan circulation, 4(16%) had double inlet left ventricle and 2(8%) had 
complex pulmonary atresia. A quarter of patients (n=7) had prior history of 
venesections, but none had been venesected in the year prior to entering the study. 
Prior bleeding episodes in these patients were relatively uncommon (4 had a history 
of hemoptysis and 1 had a spontaneous muscle hematoma).  
Mean resting oxygen saturation was 80.6±5.3% and the vast majority of 
patients were in functional class II or more (88%). Amongst patients with 
Eisenmenger syndrome, 10 (71%) were on bosentan therapy (> 3 months on a stable 
dose). Almost one half of patients were on warfarin (44%). At screening, the majority 
of patients (n=22) experienced occasional symptoms of fatigue and a few have had 
headaches (n=12), muscle weakness (n=6) or faintness (n=5).  
Average baseline hemoglobin concentration was 19.0±2.8g/dL. Average 
baseline ferritin, transferrin saturation and serum iron levels were 13.0±4.7ug/L, 
17.5±9.3% and 12.7±6.5umol/L, respectively. Among 25 participants, only 5 patients 
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had microcytosis (mean corpuscular volume (MCV)<80 fl) and only 8 had 
hypochromia (mean corpuscular hemoglobin (MCH)<28 pg/erythrocyte). 
Iron therapy 
Twenty-three patients were initiated and tolerated oral iron therapy well. Two 
patients declined oral supplementation due to severe gastrointestinal side effects from 
previous treatment and opted for intravenous therapy. The mean dose of oral iron 
supplementation (ferrous fumarate) achieved during the study was 509±160mg/day. 
The two patients who received intravenous therapy iron had a single 200mg dose of 
iron sucrose and achieved the target range of iron stores (ferritin≥50ug/L or 
ferritin≥30ug/L and transferrin saturation≥15%) after 1 month. This level was 
maintained at 2 months, thus requiring no further intravenous supplementation. 
The most common side effect of oral iron therapy was abdominal pain (25%) 
followed by constipation (17%) and diarrhea (17%) (Table 2). One patient reported a 
single episode of vomiting. There were no adverse effects reported by the 2 patients 
receiving intravenous iron. Dose reduction was required in 4 patients due to 
gastrointestinal side effects. No patients required discontinuation of iron or switch to 
intravenous treatment. Importantly, there were no cases of new or worsening 
hyperviscosity symptoms.  
Changes in iron stores and hemoglobin concentration 
Significant increase in iron stores was observed after 3 months of therapy 
(Table 3). Serum iron (13.0±6.5umol/L to 21.0±11.5umol/L, p<0.001), ferritin 
(13.3±4.7ug/L to 54.1±24.2ug/L, p<0.001), as well as transferrin saturation 
(17.8±9.6% to 34.8±23.4%, p<0.001) increased. A significant increase in hemoglobin 
concentration (19.0±2.9g/dL to 20.4±2.7g/dL, p<0.001) and MCV (86.4±9.0 to 
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91.7±6.7 fL, p<0.001) was also observed. This change was seen both in patients with 
lower (< 19.7 G/ dl, median hemoglobin level) or higher baseline hemoglobin levels 
(16.8±2.3g/dL to 18.7±2.7g/dL, p=0.002 and 21.2±1.2g/dL to 22.2±1.0g/dL, p=0.042 
respectively). However, the magnitude of change was greater in those with lower 
baseline hemoglobin concentration (Figure 2). While all patients improved their 
hematologic parameters after 3 months, 6(25%) patients just fell short of criteria for 
iron repletion (mean ferritin level and transferrin saturation levels at 25.3±2.2ug/L 
and 28.6±22.7% respectively).  
Change in exercise capacity  
Iron therapy led to a significant improvement in exercise capacity expressed as 
6MWT distance (371.7±84.7m to 402.8±74.9m, p=0.001) (Figure 3). A significant 
improvement was also observed in total exercise duration on cardiopulmonary 
exercise testing (409.0±167.2s to 431.8±202.8s p=0.022) (Table 3) but the increase in 
percentage predicted peak VO2 was not significant (40.7±9.2 to 43.8%±12.4% of 
predicted, p=0.15).  
Quality of life 
Overall, total CAMPHOR score improved significantly after treatment 
(20.7±10.9 to 16.2±10.4, p=0.001) as did both health related symptom scores (8.0±4.3 
to 6.0±3.8, p=0.007) and activity scores (5.6±3.9 to 4.8±3.8, p=0.025).  Generic QoL 
showed a non significant improvement.  
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Discussion 
Our study demonstrates that replenishing iron stores in iron deficient cyanotic 
adult patients with CHD leads to improvement in QoL and exercise capacity 
measured by exercise duration in cardiopulmonary test and 6MWT distance. This 
improvement occurred irrespective of baseline hemoglobin levels. Adverse effects 
from iron therapy were at most mild, with no new or worsening symptoms of 
hyperviscosity and no patients requiring discontinuation of therapy.  
While the criteria for diagnosing iron deficiency anemia in non-cyanotic 
patients are well-established, the definition of anemia in cyanotic erythrocytotic 
patients remains elusive. In fact, traditional diagnostic criteria for anemia do not apply 
to these patients, where “appropriate” levels of hemoglobin may vary according to 
their oxygen saturations.5 Also, other erythrocyte indices such as MCV and MCH are 
not sensitive indicators of iron deficiency in cyanotic patients.6 Although most of 
iron-depleted patients in our study had normal MCV and MCH levels, a significant 
rise in hemoglobin was observed after iron treatment. This suggests the existence of a 
state of “relative anemia” in our study population and the importance of checking iron 
stores, rather than erythrocyte indices, to identify iron deficiency in cyanotic patients.  
Systematic iron supplementation for a period of 3 months resulted in a 
significant improvement in exercise capacity measured by the 6MWT likely related to 
the increase in hemoglobin concentration. In fact, hemoglobin levels are known to 
related to exercise capacity in cyanotic CHD patients.19, 20 The average increase in 
6MWT distance of 31m is comparable to that seen in trials of advanced therapies for 
pulmonary hypertension, ranging between 16m in the trepostinil PAH study and 34m 
in the BREATHE-5.21, 22  
While total cardiopulmonary exercise time increased significantly, there was 
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only a small, non-significant increase in peak VO2. In this study, severe desaturation 
during exercise was observed and low oxygen saturation might have reduced the 
arterial-mixed venous oxygen difference and limited the increase in oxygen delivery 
(i.e. peak VO2). In fact, in the presence of left to right shunt, peak VO2 does not 
reflect maximal cardiac output during exercise and a prognostic value of peak VO2 in 
this setting is yet to be established.  6MWT distance, rather than peak VO2, has been 
used as an objective clinical endpoint in a previous randomized controlled study in 
patients with Eisenmenger syndrome.  
Cyanotic heart disease has a significant impact on QoL. It is a chronic, multi-
system disorder, associated with significant long-term morbidity impacting on many 
aspects of life (e.g. education, social).24-28 However, QoL is often overlooked in 
routine clinical practice and even in clinical trials. QoL questionnaires/scores should 
be part of the routine clinical assessment of these patients, especially when assessing 
the effects of clinical interventions. The substantial improvement in the QoL score 
seen in our study is suggestive of the adverse effect of iron deficiency on cyanotic 
patients, which can be reversed with appropriate therapy. 
Although iron replacement for iron-deficient CHD patients is currently 
recommended by adult congenital cardiologists and clinical guidelines,10, 11, 29, 30 
physicians may be concerned about ‘over treating’ these patients. This is especially 
true in iron deficient patients with high baseline levels of hemoglobin. The primary 
concern is that of a dramatic increase in red cell mass in response to iron 
supplementation causing severe hyperviscosity symptoms. However, there are no data 
to support this concern to date. In our study, short term iron replacement was not 
associated with new severe hyperviscosity symptoms, even in patients with high 
baseline hemoglobin concentration. Mild hyperviscosity symptoms are often non-
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specific and rarely require treatment once iron deficiency and dehydration have been 
excluded. Moreover, patients with higher baseline hemoglobin concentration 
demonstrated a milder response to iron supplementation (Figure 2) implying the 
presence of an adaptive mechanism. This suggests that no iron deficient patient 
should be denied treatment based on their baseline hemoglobin levels alone.  
In this study, iron supplementation was performed using the dose of iron 
recommended for non-cyanotic iron-deficient patients.31 Despite this dose being 
substantial higher than that previously recommended (66mg elemental iron/day),32, 33 
no hyperviscosity symptoms occurred in our population. Moreover, 6 (25%) patients 
were still iron deficient at the end of the study. The optimal dose of iron, which 
should be safe yet effective, remains elusive and should be a topic of further 
investigation. 
Limitations 
The definition of iron deficiency is extrapolated from the non-cyanotic 
population, in which ferritin<30ug/L has a positive predictive value of 92-98%12 
whereas transferrin saturation<15% has a sensitivity of 80% but low specificity (50-
65%).34 Although ferritin levels in normal patients range from 40-200ug/L, some 
studies have shown that low normal levels (<50ug/L) can be associated with other 
pathologic conditions.35 We therefore expanded our definition to include patients with 
a ferritin<50ug/L and transferrin saturation of <15% in an attempt to increase 
specificity. 
Even though not all patients had pulmonary hypertension, we chose to use the 
CAMPHOR score to assess quality of life in this study. This score is targeted to 
patients with pulmonary hypertension and was, thus, designed to assess patients with 
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low energy levels and significant exercise limitation, which commonly affect ordinary 
activities.15 Moreover, different to scores designed for congestive heart failure, the 
CAMPHOR score relies on the assessment of breathlessness and energy levels rather 
than peripheral oedema.15 Significant exercise limitation and early onset of dyspnea 
are common features of PAH and complex cyanotic congenital heart disease.18 We, 
thus, felt that the CAMPHOR score could be an appropriate tool in this setting 
compared to other non disease-specific questionnaires.   
The small sample size precludes subgroup analysis to identify those patients 
who benefit most from iron supplementation versus those with little or no benefit. 
Moreover, the results of the present study refer to short term supplementation and 
follow-up. Longer term studies in a larger population are needed to determine the 
efficacy and risks of chronic iron replacement. 
Finally, this was an uncontrolled prospective study. Therefore, we cannot 
exclude that the observed beneficial effects might reflect a placebo effect, rather than 
true change due to iron repletion. However, the concomitant significant improvement 
in objective measures such as hemoglobin exercise duration and 6MWT distance 
suggests otherwise. A randomized controlled study is needed to confirm the efficacy 
of iron supplementation therapy in this population. 
   
Conclusion 
Three months of systematic iron replacement therapy in iron-deficient cyanotic 
CHD patients was safe and resulted in significant improvement in exercise tolerance 
and QoL. Systematic screening for iron deficiency and appropriate replacement 
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TABLES AND FIGURES 
Table 1. Baseline clinical characteristics 
 
Clinical characteristics n=25 
Age, yrs 39.9±10.9 
Female gender, n (%) 20 (80) 
New York Heart Association  
Class I, n (%) 3 (12) 
Class II, n (%) 17 (68) 
Class III, n (%) 5 (20) 
Diagnoses  
Eisenmenger syndrome, n (%) 14 (56) 
Ventricular septal defect, n  10 
Patent ductus arteriosus, n  2  
Atrioventricular septal defect, n  1  
Truncus arteriosus, n  1  
Fontan circulation, n (%) 5 (20) 
Double inlet left ventricle, n (%) 4 (16) 
Pulmonary atresia with ventricular septal defect, n (%) 2 (8) 
Past history  
Thrombosis+, n (%) 1 (4) 
Venesection, n (%) 7 (28) 
Hemoptysis, n (%) 4 (16) 
Bleeding# (others), n (%) 1 (4) 
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Menorrhagia, n (%) 0 (0) 
Vegetarian diet, n (%) 0 (0) 
Medications   
Advanced therapy for pulmonary arterial hypertension, n (%) 10 (40) 
Warfarin, n (%) 11(44) 
Furosemide, n (%) 3 (12) 
Digoxin, n (%) 2 (8) 
Beta-blockers, n (%) 4 (16) 
Symptoms associated with hyperviscosity  
Headache, n (%) 12 (48) 
Faintness, n (%) 5 (20) 
Altered mentation, n (%) 0 (0) 
Visual disturbance, n (%) 2 (8) 
Parasthesia, n (%) 2(8) 
Tinnitus, n (%) 2 (8) 
Fatigue, n (%) 22(88) 
Muscle weakness, n (%) 6 (24) 
All patients with hyperviscosity symptoms had mild symptoms except for 3 patients: 2 
had moderate fatigue and 1 patient with moderate symptoms of muscle weakness. 
+ cerebrovascular accident 










Hyperviscosity symptoms†  
New and persistent n (%) 0 (0) 
Worsening symptoms n (%) 0 (0) 
Adverse effects of iron therapy  
Constipation n (%) 4 (17) 
Vomiting n (%) 1 (4) 
Abdominal pain n (%) 6 (25) 
Diarrhea n (%) 4 (17) 
Patients needing to discontinue treatment n (%) 0 (0) 
Patients needing to reduce iron dose n (%) 4 (17) 
 












Table 3. Test results before and after iron therapy 
 
Tests conducted Baseline End of study  
(3 months) 
P value 
Laboratory tests    
Hemoglobin, g/dL 19.0±2.9 20.4±2.7 <0.001 
Packed Cell Volume 57.1±9.7 61.4±8.2 <0.001 
Red blood cell count, x1012/L 6.7±0.9 6.7±0.9 0.44 
Mean cell corpuscular volume, fL 86.4±9.0 91.7±6.7 <0.001 
Mean corpuscular hemoglobin, pg 29.0±3.5 30.7±2.9 <0.001 
Mean corpuscular hemoglobin concentration, g/dL 33.3±1.0 33.3±1.0 1.00 
Ferritin, ug/L 13.3±4.7 54.1±24.2 <0.001 
Serum iron, umol/L 13.0±6.5 21.0±11.5 <0.001 
Transferrin saturation, % 17.8±9.6 34.8±23.4 <0.001 
Creatinine, umol/L 77.8±14.3 76.9±15.1 0.77 
Alanine transaminase, IU/L 25.6±11.3 26.3±12.3 0.30 
Six minute walk test    
Walk distance, m 371.7±84.7 402.8±74.9 0.001 
Starting heart rate, beats/min 81.4±13.5 79.6±13.1 0.10 
Peak heart rate, beats/min 100±19.4 98.6±17.5 0.45 
Pre-test Borg score 0.4±1.0 0.7±1.7 0.80 
Post-test Borg score 4.2±2.4 4.3±2.7 0.94 
Post-test oxygen saturation, % 69.4±10.0 66.8±9.3 0.17 
Cardiopulmonary exercise testing    
Peak VO2, ml/kg/min 13.9±2.9 14.6±3.9 0.18 
% predicted peak VO2 40.7±9.2 43.8±12.4 0.15 
VE/VCO2 slope 53.6±3.6 53.1±17.0 0.64 
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Respiratory exchange ratio at peak 1.0±0.1 0.9±0.1 0.15 
Total exercise duration, s 409.0±167.2 431.8±202.8 0.022 
Peak exercise oxygen saturation, % 65.5±12.4 62.9±12.7 0.23 
Peak heart rate, beats/min 134.6±25.6 136.0±23.3 0.94 
Heart rate reserve, beats/min  52.8±18.1 53.5±27.0 0.89 
CAMPHOR questionnaire+    
Symptom score 8.0±4.3 6.0±3.8 0.007 
Activity score 5.6±3.9 4.8±3.8 0.025 
QoL score 7.1±5.5 6.0±5.1 0.12 
Total score 20.7±10.9 16.2±10.4 0.001 
Peak VO2 indicates peak oxygen consumption; QoL, Quality of Life 























Figure 1: Study Protocol. The study protocol is presented demonstrating the 




Figure 2: Change (increase) in hemoglobin concentration over baseline hemoglobin 
levels. The change (increase) in hemoglobin levels after three months of iron 
replacement for all patients is shown. The increase is observed in patients of varying 
baseline hemoglobin levels. There is a trend towards a greater magnitude of increase 
in those who started with lower baseline hemoglobin and less in those who started at 
higher levels. This may suggest an adaptive mechanism.  
 
 
Figure 3: Improvement in six minute walk test distance and total CAMPHOR scores.  
The improvement in total quality of life (QoL) scores on the CAMPHOR disease-
specific questionnaire is shown with the mean±SD depicted at the top of the figure. 
The improvement in six minute walk test distance is similarly displayed on the right. 
  
 
 
 
 
